News
Public · Published
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
SELLAS Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached the pre-specified 80th event, the number of deaths. This triggers database lock, unblinding and final analysis, with topline primary endpoint results expected this quarter.
Published:
Updated:
What happened
SELLAS Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached the pre-specified 80th event, the number of deaths. This triggers database lock, unblinding and final analysis, with topline primary endpoint results expected this quarter.
Confirmed
Global impact / market context
This trial result is a key decision point for SELLAS, because success or failure can reshape how investors value the company's lead treatment and its ability to fund further development of galinpepimut-S, which means the drug candidate being tested.
Analyst inference
The company says AML patients in second complete remission have limited treatment options. A positive overall survival result could support regulatory talks and partnerships, while a negative result would likely reduce expectations for this program and make future financing harder.
Analyst inference
What to watch
- The company plans to announce preliminary topline primary endpoint results this quarter, following database lock, unblinding and statistical analysis under the study's pre-specified statistical analysis plan, which means the pre-set rules for analyzing the data. Confirmed
- Watch whether the reported overall survival result meets the trial's pre-specified statistical goal, and whether SELLAS discloses the size of the survival benefit and any safety findings from the unblinded data. Proposed
- Track how the result affects SELLAS's ability to raise cash or find a partner, since a late-stage trial outcome can change spending plans, borrowing costs and investor positioning in the stock. Analyst inference